Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
2 patients and there was no grade 4/5 hypercalcaemia.
I · Intervention 중재 / 시술
no prior systemic chemotherapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our study has implications for interpretation and design of clinical trials incorporating paricalcitol for patients with advanced pancreatic cancer. [TRIAL REGISTRATION] ClinicalTrials.gov identifier: NCT04617067, registration date 10/27/2020.
[BACKGROUND] Pancreatic cancer (PDAC) often responds poorly to chemotherapy, represents an unmet clinical need and new therapeutic approaches are urgently required.
APA
Easty D, McDermott R, et al. (2026). Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer.. BMC cancer, 26(1), 255. https://doi.org/10.1186/s12885-025-14512-2
MLA
Easty D, et al.. "Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer.." BMC cancer, vol. 26, no. 1, 2026, pp. 255.
PMID
41535788 ↗
Abstract 한글 요약
[BACKGROUND] Pancreatic cancer (PDAC) often responds poorly to chemotherapy, represents an unmet clinical need and new therapeutic approaches are urgently required. Desmoplasia is a hallmark of PDAC. Multiple preclinical studies suggest cancer associated fibroblasts (CAF) support cancer growth, and attention has recently turned towards inclusion of anti-stromal agents into chemotherapy trials. Our objective was to evaluate safety and tolerability of oral paricalcitol in combination with systemic chemotherapy in patients with advanced PDAC.
[METHODS] This was a phase II, single-arm study in patients with advanced PDAC who had received no prior systemic chemotherapy. Gemcitabine and NAB-paclitaxel were administered weekly for 3 of every 4 weeks (days 1, 8 and 15) and paricalcitol administered orally every day of a 28-day cycle. Patients were treated until disease progression with an interim analysis. The primary efficacy endpoint was progression free survival (PFS). Secondary efficacy endpoints were evaluation of overall survival (OS), time to treatment failure (TTF) and tumour response rate (TRR).
[RESULTS] Fifteen patients were enrolled. Median PFS was 14.6 weeks with 95% CI of (7.9–24.0). Estimated PFS rate at 24 weeks was 18.0% with 95% CI of (2.9–43.4). Five patients achieved stable disease; one achieved a partial response. Confirmed tumour response rate was 8.3% with 90% CI of (0.4–33.9). Mild hypercalcaemia, previously associated with vitamin D receptor agonists, occurred in nine (60%) patients, moderate (Grade 3) hypercalcaemia in 2 patients and there was no grade 4/5 hypercalcaemia. The study did not meet its primary objective and discontinued following interim analysis.
[CONCLUSIONS] Oral paricalcitol was safely combined with chemotherapy. The prespecified efficacy threshold for 6-month progression free survival probability (≥ 70%) was not met. The study was stopped early after the planned interim analysis as the criterion pre-specified in order to move to the next stage of the study was not met. Efficacy of paricalcitol in advanced PDAC was lower than expected, with a non-significant trend towards decreased PFS. Our study has implications for interpretation and design of clinical trials incorporating paricalcitol for patients with advanced pancreatic cancer.
[TRIAL REGISTRATION] ClinicalTrials.gov identifier: NCT04617067, registration date 10/27/2020.
[METHODS] This was a phase II, single-arm study in patients with advanced PDAC who had received no prior systemic chemotherapy. Gemcitabine and NAB-paclitaxel were administered weekly for 3 of every 4 weeks (days 1, 8 and 15) and paricalcitol administered orally every day of a 28-day cycle. Patients were treated until disease progression with an interim analysis. The primary efficacy endpoint was progression free survival (PFS). Secondary efficacy endpoints were evaluation of overall survival (OS), time to treatment failure (TTF) and tumour response rate (TRR).
[RESULTS] Fifteen patients were enrolled. Median PFS was 14.6 weeks with 95% CI of (7.9–24.0). Estimated PFS rate at 24 weeks was 18.0% with 95% CI of (2.9–43.4). Five patients achieved stable disease; one achieved a partial response. Confirmed tumour response rate was 8.3% with 90% CI of (0.4–33.9). Mild hypercalcaemia, previously associated with vitamin D receptor agonists, occurred in nine (60%) patients, moderate (Grade 3) hypercalcaemia in 2 patients and there was no grade 4/5 hypercalcaemia. The study did not meet its primary objective and discontinued following interim analysis.
[CONCLUSIONS] Oral paricalcitol was safely combined with chemotherapy. The prespecified efficacy threshold for 6-month progression free survival probability (≥ 70%) was not met. The study was stopped early after the planned interim analysis as the criterion pre-specified in order to move to the next stage of the study was not met. Efficacy of paricalcitol in advanced PDAC was lower than expected, with a non-significant trend towards decreased PFS. Our study has implications for interpretation and design of clinical trials incorporating paricalcitol for patients with advanced pancreatic cancer.
[TRIAL REGISTRATION] ClinicalTrials.gov identifier: NCT04617067, registration date 10/27/2020.